Devayani Machiraju

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Baseline dual-energy CT iodine uptake predicts systemic but not lesion-level progression in immunotherapy-treated metastatic melanoma.

Baseline dual-energy CT iodine uptake predicts systemic but not lesion-level progression in immunotherapy-treated metastatic melanoma.

Journal: European journal of radiology

Published: June 02, 2026

Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study.

Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study.

Journal: European journal of nuclear medicine and molecular imaging

Published: July 02, 2025

Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies.

Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 17, 2025

The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma.

The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma.

Journal: Oncoimmunology

Published: December 24, 2024

CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients.

CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients.

Journal: Cancer immunology, immunotherapy : CII

Published: March 28, 2024

Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients.

Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients.

Journal: Cancers

Published: February 02, 2024

Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action.

Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action.

Journal: The Journal of investigative dermatology

Published: October 30, 2023

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma.

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma.

Journal: Frontiers in medicine

Published: December 06, 2022

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients.

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients.

Journal: Frontiers in oncology

Published: October 18, 2022

Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA).

Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA).

Journal: Oncoimmunology

Published: April 28, 2022

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma.

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma.

Journal: Cancers

Published: January 25, 2022

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.

Journal: Life (Basel, Switzerland)

Published: October 26, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026